Italy
With over six years of experience in diagnostics and medical affairs, I currently serve as a Clinical Research Scientist at Eli Lilly and Company, contributing to innovative solutions in diagnostic strategies and advancements. My focus lies in diagnostics and medical affairs, where I collaborate with cross-functional teams to deliver actionable insights and support strategic initiatives. I am committed to driving impactful outcomes that align with Eli Lilly's mission to make life better for people worldwide.
Monitor and analysis of latest evolving trends and technologies in the diagnostic testing market. Develop biomarker and disease pipeline for companion diagnostic testing to provide client-specific market guidance in Europe, Asia, US and Latam. Provide accurate actionable scientific, medical and and intelligence data analysis to provide local/regional strategies and tactics. Review viability and impact of strategic initiatives based on scientific and medical data assessment in liaison with sales, global laboratory, marketing and product development teams.
Management and coordination of national Laboratory Diagnostic Liaison country teams field- based activities (Spain, Italy, France, Portugal).
Established and expanded substantially local network of thought leaders in health care, investigators, National Scientific Societies, External quality assessment institutions and HCP group experts.
• Study of a conditional p130Cas knockout mice in the epidermis. Identification of p130Cas as an important modulator of mouse keratinocyte differentation. • Study of the role of p130Cas in the estrogen receptor (ER) and the epithelial growth factor receptor (EGFR) crosstalk by using an ex-vivo model of mouse mammary epithelial cells. • Analysis of the role of p130Cas in mammary stem/progenitor population and in cancer stem cells. p130Cas in mammary stem/progenitor population and in cancer stem cells. • Identification of the molecular mechanisms through which p130Cas induces ErbB2 tumorigenesis and invasiveness.
Breast cancer Research • In vivo and in vitro studies of the consequence of the over-expression of the adaptor protein p130Cas during mouse mammary gland development • Study of the role of p130Cas in ErbB2-dependent breast cancer. • Study of the role of p140Cap in Erbb2-dependent cancer
Development and application of experimental in vitro technology during the initial steps of drug discovery.
Scouting, selection and analysis of the feasibility of funding opportunities in the fields of biochemistry and biotechnology at the EU level